Product Description
Betrixaban is used to prevent venous thromboembolism (VTE) in hospitalized patients at risk for blood clots because of the loss or decreased ability to move around or due to other factors. Betrixaban is a factor Xa inhibitor, an anticoagulant. It works by decreasing the clotting ability of the blood and helps prevent harmful clots from forming in the blood vessels. (Sourced from: https://www.mayoclinic.org/drugs-supplements/betrixaban-oral-route/description/drg-20406393)
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | European Medicines Agency
Approved Indications: Embolism | Thromboembolism | Venous Thromboembolism
Known Adverse Events: Injuries/wounds Unspecified
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Venous Thromboembolism
Phase 2: Healthy Volunteers|Injuries/wounds Unspecified|Stroke|Atrial Fibrillation|Atrial Flutter|Thromboembolism
Phase 1: Healthy Volunteers|Venous Thromboembolism|Neuromyelitis Optica|Embolism and Thrombosis|Tic Disorders|Venous Thrombosis|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Protocol 16-021 â Pediatric PK | P1 |
Terminated |
Tic Disorders|Embolism and Thrombosis|Venous Thrombosis|Venous Thromboembolism|Neuromyelitis Optica |
2020-08-05 |
|
| NCT03346083 | P1 |
Terminated |
Venous Thromboembolism |
2019-10-08 |
|
| NCT03397888 | P1 |
Completed |
Healthy Volunteers |
2018-01-16 |
22% |
| NCT03330457 | P2 |
Terminated |
Healthy Volunteers|Injuries/wounds Unspecified |
2016-02-22 |